JP2017534618A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534618A5
JP2017534618A5 JP2017521988A JP2017521988A JP2017534618A5 JP 2017534618 A5 JP2017534618 A5 JP 2017534618A5 JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017534618 A5 JP2017534618 A5 JP 2017534618A5
Authority
JP
Japan
Prior art keywords
criteria
sirs
terlipressin
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017521988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534618A (ja
JP6673915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056861 external-priority patent/WO2016065117A1/en
Publication of JP2017534618A publication Critical patent/JP2017534618A/ja
Publication of JP2017534618A5 publication Critical patent/JP2017534618A5/ja
Priority to JP2019155678A priority Critical patent/JP6989571B2/ja
Application granted granted Critical
Publication of JP6673915B2 publication Critical patent/JP6673915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017521988A 2014-10-24 2015-10-22 １型肝腎症候群患者の治療方法 Active JP6673915B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019155678A JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US62/068,357 2014-10-24
US201562151384P 2015-04-22 2015-04-22
US62/151,384 2015-04-22
PCT/US2015/056861 WO2016065117A1 (en) 2014-10-24 2015-10-22 Method of treating patients with hepatorenal syndrome type 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019155678A Division JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法

Publications (3)

Publication Number Publication Date
JP2017534618A JP2017534618A (ja) 2017-11-24
JP2017534618A5 true JP2017534618A5 (https=) 2018-09-27
JP6673915B2 JP6673915B2 (ja) 2020-03-25

Family

ID=54478246

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017521988A Active JP6673915B2 (ja) 2014-10-24 2015-10-22 １型肝腎症候群患者の治療方法
JP2019155678A Active JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法
JP2021102221A Active JP7346494B2 (ja) 2014-10-24 2021-06-21 １型肝腎症候群患者の治療方法
JP2022146052A Withdrawn JP2022171795A (ja) 2014-10-24 2022-09-14 １型肝腎症候群患者の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019155678A Active JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法
JP2021102221A Active JP7346494B2 (ja) 2014-10-24 2021-06-21 １型肝腎症候群患者の治療方法
JP2022146052A Withdrawn JP2022171795A (ja) 2014-10-24 2022-09-14 １型肝腎症候群患者の治療方法

Country Status (15)

Country Link
US (2) US10335452B2 (https=)
EP (3) EP3209317B1 (https=)
JP (4) JP6673915B2 (https=)
CN (2) CN107206049B (https=)
AU (1) AU2015335855A1 (https=)
CA (1) CA2965325A1 (https=)
DK (2) DK3978074T3 (https=)
ES (2) ES2987577T3 (https=)
FI (1) FI3978074T3 (https=)
HR (1) HRP20220225T1 (https=)
HU (1) HUE058066T2 (https=)
PL (2) PL3209317T3 (https=)
PT (2) PT3978074T (https=)
SI (1) SI3209317T1 (https=)
WO (1) WO2016065117A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
HUE058066T2 (hu) * 2014-10-24 2022-06-28 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin 1-es típusú hepatorenális szindróma kezelésére
CA3037581A1 (en) * 2016-10-21 2018-04-26 Chiasma, Inc. Terlipressin compositions and their methods of use
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
US20210128676A1 (en) * 2019-10-30 2021-05-06 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
WO2008112563A1 (en) * 2007-03-09 2008-09-18 Flowmedica, Inc. Acute kidney injury treatment systems and methods
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9464284B2 (en) 2009-03-09 2016-10-11 Bioatla, Llc Mirac proteins
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
HUE058066T2 (hu) * 2014-10-24 2022-06-28 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin 1-es típusú hepatorenális szindróma kezelésére
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Similar Documents

Publication Publication Date Title
JP2017534618A5 (https=)
Cairo et al. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation
JP6989571B2 (ja) １型肝腎症候群患者の治療方法
JP2016516016A5 (https=)
Grünig et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial
CN114786662A (zh) 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途
JP2023113870A (ja) Ｂ因子阻害剤の使用方法
Fedorak et al. VSL3 probiotic mixture induces remission in patients with active ulcerative colitis
JP2006502231A5 (https=)
Takaha et al. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer
Jakacki et al. Dose‐intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas
Shimizu et al. Long-term evaluation of partial splenic embolization followed by interferon therapy in patients with hepatitis C virus (HCV) cirrhosis and thrombocytopenia
Sultan et al. Effect of an Online Hemodiafiltration (OL-HDF) Session in Children with Chronic Kidney Disease Stage 5 on Circulating Neutrophil Extracellular Traps (NETs).
Bazarbachi et al. Non-transfusion-dependent thalassaemia: a panoramic survey from pathophysiology to treatment
Kiskaddon et al. Continuous intravenous sildenafil use, dose titration, tolerability and clinical outcomes in children with pulmonary hypertension.
Yie et al. A Case Report of Transfusion-related Acute Lung Injury (TRALI) Type II from A Heathy Male Donor
Lee et al. The Experience and Management of Two Cases of Metformin-associated Lactic Acidosis
Glezerman Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis
Khalil et al. Breakthrough Severe COVID-19 Infection After Triple Dose Pfizer Vaccination.
Curry et al. Benefit-to-risk profile in the label-specific population of patients with hepatorenal syndrome-acute kidney injury treated with terlipressin
Michael et al. Relationship of baseline weight and response to lumasiran in patients with primary hyperoxaluria type 1 on hemodialysis
Lee et al. A case of acute pulmonary thromboembolism after taking tadalafil
Sciascia et al. Exploring clinical and pharmacological effects of nalbuphine HCl oral tablets in hemodialysis subjects with pruritus
Godin et al. EVALUATION OF THE INTERACTION BETWEEN DESIPRAMINE ADMINISTERED ORALLY AND COCAINE ADMINISTERED INTRAVENOUSLY IN DOGS
Kaidi et al. USE OF TELEMETRY IN RATS TO SCREEN KINASE INHIBITORS FOR CARDIOVASCULAR EFFECTS